{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:51:14Z","timestamp":1782323474041,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the impact of maternal cytomegalovirus (CMV) viral load at the time of intervention by valacyclovir (VCV) in preventing maternal\u2013fetal transmission following primary CMV infection in early pregnancy and to assess the effect of VCV on maternal viral load kinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a retrospective, observational, dual-center study including pregnant women referred for suspected primary CMV infection during the periconceptional period or first trimester, based on serological screening performed. Primary infection was subsequently confirmed according to predefined criteria. Maternal viral load was measured by quantitative PCR on whole blood at the time of initial evaluation in the perinatal center, before treatment initiation. Patients were analyzed according to viral load status (negative, detectable, or quantifiable) and whether they received high-dose oral VCV (8\u2005g\/day). The primary outcome was congenital CMV infection, confirmed by neonatal urine PCR. Secondary outcomes included maternal viral load kinetics and their relationship to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 133 patients were included (90 VCV, 43 untreated). At diagnosis (median 14 weeks of gestation), 31 (24%) had negative viral load, 48 (36%) detectable, and 54 (40%) quantifiable viral load. No congenital CMV infections occurred in patients with negative viral load, regardless of treatment. Among those with quantifiable viral load, VCV was associated with lower risk of transmission compared to untreated controls (21% vs 58%; P = .028). For detectable but not quantifiable viral load, transmission rates did not differ. Longitudinally, viral load declined faster in treated patients (slope \u22120.3059 vs \u22120.1334; P = .003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maternal CMV viral load may serve as a useful prognostic indicator after primary infection in early pregnancy. Its presence could help identify a subgroup at increased risk of vertical transmission who might benefit from VCV. Conversely, negative viral load appears to be associated with a lower likelihood of fetal infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag291","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:39:40Z","timestamp":1782214780000},"source":"Crossref","is-referenced-by-count":0,"title":["Maternal Cytomegalovirus Viral Load Correlates With the Risk of Congenital Infection and With Antiviral Therapy Response in Early Pregnancy"],"prefix":"10.1093","volume":"13","author":[{"given":"Charles","family":"Egloff","sequence":"first","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris APHP.Nord, Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Louis Mourier , Colombes ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG) , Velizy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Vauloup Fellous","sequence":"additional","affiliation":[{"name":"Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG) , Velizy ,","place":["France"]},{"name":"INSERM U1184, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB\/IDMIT), Paris Saclay University , Fontenay-aux-Roses ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Paris, Division of Virology, Laboratoire de Biologie M\u00e9dicale de R\u00e9f\u00e9rence \u201cVirus et P\u00e9rinatalit\u00e9\u201d \u201cPaul Brousse\u201d Hospital, Paris Saclay University Hospitals , Villejuif ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadhira","family":"Houhou-Fidouh","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, Virology Department, Bichat Hospital, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Benachi","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, Department of Obstetrics and Gynecology, DMU Sant\u00e9 des Femmes et des Nouveau-n\u00e9s, Antoine B\u00e9cl\u00e8re Hospital, Paris Saclay University , Clamart ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5883-7597","authenticated-orcid":false,"given":"Laurent","family":"Mandelbrot","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris APHP.Nord, Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Louis Mourier , Colombes ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG) , Velizy ,","place":["France"]},{"name":"INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-0047","authenticated-orcid":false,"given":"Alexandre J","family":"Vivanti","sequence":"additional","affiliation":[{"name":"Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG) , Velizy ,","place":["France"]},{"name":"Assistance Publique-H\u00f4pitaux de Paris, Department of Obstetrics and Gynecology, DMU Sant\u00e9 des Femmes et des Nouveau-n\u00e9s, Antoine B\u00e9cl\u00e8re Hospital, Paris Saclay University , Clamart ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Picone","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris APHP.Nord, Service de Gyn\u00e9cologie Obst\u00e9trique, H\u00f4pital Louis Mourier , Colombes ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG) , Velizy ,","place":["France"]},{"name":"INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026062413263115500_ofag291-B1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.12688\/f1000research.12517.1","article-title":"Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention","volume":"7","author":"Pass","year":"2018","journal-title":"F1000Res"},{"key":"2026062413263115500_ofag291-B2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"2026062413263115500_ofag291-B3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajog.2023.07.022","article-title":"The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis","volume":"230","author":"Chatzakis","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"2026062413263115500_ofag291-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2023.101101","article-title":"Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: real-life data from Italy (MEGAL-ITALI study)","volume":"5","author":"Zammarchi","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2026062413263115500_ofag291-B5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/uog.26039","article-title":"New data on efficacy of valacyclovir in secondary prevention of maternal\u2013fetal transmission of cytomegalovirus","volume":"61","author":"Egloff","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026062413263115500_ofag291-B6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0398-7620(05)84739-X","article-title":"D\u00e9pistage pr\u00e9natal du cytom\u00e9galovirus en France\u202f: une augmentation des pratiques de prescription de 2000 \u00e0 2003 malgr\u00e9 l\u2019absence de recommandation favorable","volume":"53","author":"Moty-Monnereau","year":"2005","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"key":"2026062413263115500_ofag291-B7","article-title":"D\u00e9pistage des maladies infectieuses en cours de grossesse\u202f: r\u00e9sultats de l\u2019enqu\u00eate Elfe en maternit\u00e9s, France m\u00e9tropolitaine, 2011","author":"Richaud-Eyraud","year":"2015","journal-title":"Bulletin Epid\u00e9miologique Hebdomadaire"},{"key":"2026062413263115500_ofag291-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104641","article-title":"Positive predictive values of CMV-IgM and importance of CMV-IgG avidity testing in detecting primary infection in three different clinical settings. A French retrospective cohort study","volume":"132","author":"P\u00e9rillaud-Dubois","year":"2020","journal-title":"J Clin Virol"},{"key":"2026062413263115500_ofag291-B9","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1093\/cid\/ciaf437","article-title":"Cytomegalovirus vertical transmission rate according to IgG avidity value and valacyclovir treatment of maternal primary infection in the first trimester of pregnancy","volume":"81","author":"Fourgeaud","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026062413263115500_ofag291-B10","article-title":"Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI)","volume":"40","author":"Leruez-Ville","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026062413263115500_ofag291-B11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/diagnostics11030396","article-title":"Pitfalls in the serological diagnosis of primary human cytomegalovirus infection in pregnancy due to different kinetics of IgM clearance and IgG avidity Index maturation","volume":"11","author":"Sarasini","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026062413263115500_ofag291-B12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jviromet.2017.08.004","article-title":"Clinical evaluation of the new Roche platform of serological and molecular cytomegalovirus-specific assays in the diagnosis and prognosis of congenital cytomegalovirus infection","volume":"248","author":"Chiereghin","year":"2017","journal-title":"J Virol Methods"},{"key":"2026062413263115500_ofag291-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2015.09.002","article-title":"Evaluation of the new LIAISON \u00ae CMV IgG, IgM and IgG avidity II assays","volume":"72","author":"Delforge","year":"2015","journal-title":"J Clin Virol"},{"key":"2026062413263115500_ofag291-B14","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/JCM.02172-08","article-title":"Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays","volume":"47","author":"Lagrou","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2026062413263115500_ofag291-B15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s10096-014-2109-8","article-title":"Analytical issues possibly affecting the performance of commercial human cytomegalovirus IgG avidity assays","volume":"33","author":"Berth","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026062413263115500_ofag291-B16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcv.2012.10.017","article-title":"Re-evaluation of the VIDAS\u00ae cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV\u2013IgG maturation","volume":"56","author":"Vauloup-Fellous","year":"2013","journal-title":"J Clin Virol"},{"key":"2026062413263115500_ofag291-B17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcv.2016.07.005","article-title":"Monitoring of human cytomegalovirus DNAemia during primary infection in transmitter and non-transmitter mothers","volume":"82","author":"Zavattoni","year":"2016","journal-title":"J Clin Virol"},{"key":"2026062413263115500_ofag291-B18","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/v14102137","article-title":"Contribution of Serum cytomegalovirus PCR to diagnosis of early CMV primary infection in pregnant women","volume":"14","author":"P\u00e9rillaud-Dubois","year":"2022","journal-title":"Viruses"},{"key":"2026062413263115500_ofag291-B19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10096-015-2537-0","article-title":"Evaluation of a standardised real-time PCR based DNA-detection method (Realstar\u00ae) in whole blood for the diagnosis of primary human cytomegalovirus (CMV) infections in immunocompetent patients","volume":"35","author":"Berth","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026062413263115500_ofag291-B20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/v13050816","article-title":"CMV-Specific Cell-Mediated immunity in immunocompetent adults with primary CMV infection: a case series and review of the literature","volume":"13","author":"Chiereghin","year":"2021","journal-title":"Viruses"},{"key":"2026062413263115500_ofag291-B21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/cid\/ciw700","article-title":"Congenital cytomegalovirus infection: prognostic value of maternal DNAemia at amniocentesis","volume":"64","author":"Simonazzi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026062413263115500_ofag291-B22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/cid\/cit059","article-title":"Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort","volume":"56","author":"Leruez-Ville","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026062413263115500_ofag291-B23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","article-title":"Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences","volume":"223","author":"Chatzakis","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2026062413263115500_ofag291-B24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104983","article-title":"Early detection of active human CytomegaloVirus (hCMV) infection in pregnant women using data generated for noninvasive fetal aneuploidy testing","volume":"100","author":"Faas","year":"2024","journal-title":"eBioMedicine"},{"key":"2026062413263115500_ofag291-B25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/uog.29221","article-title":"Metagenomic analysis of NIPT raw data suggests high negative predictive value for congenital cytomegalovirus infection screening","volume":"65","author":"Bourgon","year":"2025","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026062413263115500_ofag291-B26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/14767058.2016.1169521","article-title":"Cytomegalovirus non-primary infection during pregnancy. Can serology help with diagnosis?","volume":"30","author":"Picone","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2026062413263115500_ofag291-B27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/infdis\/jiad412","article-title":"Reconsideration of maternal serological testing for predicting congenital CMV infection","volume":"229","author":"Huang","year":"2024","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag291\/68606774\/ofag291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag291\/68606774\/ofag291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:26:39Z","timestamp":1782321999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag291\/8715640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag291","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag291"}}